Comparative Pharmacology
Head-to-head clinical analysis: CARBON DIOXIDE USP versus DOPRAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBON DIOXIDE USP versus DOPRAM.
CARBON DIOXIDE, USP vs DOPRAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbon dioxide acts as a respiratory stimulant via central and peripheral chemoreceptors, increases cerebral blood flow through vasodilation, and affects acid-base balance by forming carbonic acid.
Doxapram (DOPRAM) is a respiratory stimulant that acts primarily by stimulating peripheral chemoreceptors in the carotid body, leading to increased respiratory drive. It also has central effects at higher doses by activating the medullary respiratory center.
5% carbon dioxide with 95% oxygen or 10% carbon dioxide with 90% oxygen, inhaled via face mask or ventilator, titrated to achieve arterial pCO2 of 35-45 mmHg; typically 1-2 L/min, adjusted based on clinical response.
1-3 mg/kg intravenous bolus over 30-60 seconds, may repeat in 15 minutes up to a total of 3 mg/kg; for respiratory stimulation, continuous IV infusion at 1-5 mg/kg/hour.
None Documented
None Documented
The terminal elimination half-life of CO2 is approximately 1-3 minutes, reflecting rapid equilibration with body stores (primarily bicarbonate and carbamino compounds). This short half-life allows for minute-to-minute adjustments by ventilation. Clinically, changes in ventilation lead to new steady-state CO2 levels within 5-10 minutes.
2-4 hours in adults; prolonged in hepatic impairment or neonates.
Carbon dioxide is eliminated almost entirely via the lungs as a gas. In steady state, approximately 60-70% of CO2 is transported as bicarbonate in plasma and rapidly equilibrated with alveolar gas. Renal excretion is negligible (<1%) under normal conditions, as bicarbonate is reabsorbed; however, in metabolic acidosis, renal excretion of H+ and reclamation of bicarbonate can increase, but direct CO2 excretion remains pulmonary.
Renal (unchanged drug and metabolites; approximately 20-30% as unchanged doxapram).
Category C
Category C
Respiratory Stimulant
Respiratory Stimulant